Background: The availability of HIV antiretroviral therapy (ART) has been associated with the development of\ntransmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients\ninitiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion\nof TDRM in treatment-naÃ?¯ve, recently infected HIV-positive individuals sampled from four urban locations across Asia\nbetween 2007ââ?¬â??2010.\nMethods: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance ââ?¬â?? Surveillance Study (TASER-S) were\ngenotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list.\nResults: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong:\n3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI\n(0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time\nacross all four clinical settings.\nConclusions: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines\nwas low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the\nscale-up of ART at higher CD4 levels.
Loading....